Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01319630 · ClinicalTrials.gov registry record

The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients

A clinical trial, sponsored by Mercy Research.

Completed
Registry status
45
Enrollment target

NCT01319630: Completed study, sponsored by Mercy Research.

NCT01319630 is a clinical trial that has completed, run by Mercy Research. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01319630 has completed, sponsored by Mercy Research.

COMPLETED
Registry status
45 participants
Enrollment target

Study Summary

Major microvascular blood flow alterations have been documented in patients with severe sepsis. It was also demonstrated that the microcirculation improved in survivors of septic shock but failed to do so in patients dying from acute circulatory failure or with multiple organ failure after shock resolution. Early, effective fluid resuscitation is a key component in the management of patients with severe sepsis and septic shock with the goal of improving tissue perfusion. The best fluid in this early resuscitation phase has been and still is under debate. The aim of this study is to evaluate the effect of Three different Fluids(Albumin 5%, Normal Saline, HES 130 kD) on microcirculation in severe sepsis/septic shock patients using Sidestream Dark Field (SDF) Microscopy and Near-Infrared Spectroscopy (NIRS) analysis.

Primary Outcome

obtained by Sidestream Dark Field (SDF) microscopy

Interventions

  • DEVICE Near Infrared Spectroscopy (NIRS)
  • DEVICE Sidestream Dark Field (SDF)

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2011-04
Est. Completion 2016-04
Mercy Research

14 total trials

What the finished NCT01319630 record still lists

NCT01319630 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Near Infrared Spectroscopy (NIRS) is the first listed.

NCT01319630 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01319630 about?

NCT01319630 is a clinical study titled "The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients". Major microvascular blood flow alterations have been documented in patients with severe sepsis. It was also demonstrated that the microcirculation improved in survivors of septic shock but failed to do so in patients dying from acute circulatory failure or with multiple organ failure after shock res...

What is the current status of trial NCT01319630?

This trial is currently completed. The enrollment target is 45 participants. The study started on 2011-04. Estimated completion is 2016-04.

What interventions are being tested in trial NCT01319630?

The interventions under investigation include: Near Infrared Spectroscopy (NIRS) (DEVICE), Sidestream Dark Field (SDF) (DEVICE).

Who is sponsoring clinical trial NCT01319630?

This trial is sponsored by Mercy Research, which has 14 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01319630, the US trial registry maintained by the National Library of Medicine. NCT01319630 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.